

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	La Colla <i>et al.</i>	Confirmation No.:	9201
Serial No.:	10/609,298	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No: (CAM:	11874-016-999 417451-999016) IDX 1017

REQUEST TO CORRECT INVENTORSHIP UNDER 37 C.F.R. 1.48(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The following were originally named inventors in the above-referenced U.S. non-provisional patent application:

Paolo La Colla

Jean-Pierre Sommadossi

Richard Storer

Gilles Gosselin.

This Paper corrects the inventorship in the above-referenced application under 37 C.F.R. § 1.48(a) to be:

Jean-Pierre Sommadossi

Paolo La Colla

Gilles Gosselin.

Thus, this Paper corrects the inventorship in the above-referenced application by deleting Richard Storer. A Statement of Richard Storer in compliance with 37 C.F.R. §1.48(a) is enclosed. A Declaration signed by inventors Sommadossi, La Colla and Gosselin is enclosed.

Consent to the above correction of inventorship from Assignees Idenix Pharmaceuticals, Inc., Centre National De La Recherche Scientifique, Universita Degli Studi Di Cagliari and L'Université Montpellier II are also enclosed, as is a Power of Attorney by L'Université

Montpellier II. Powers of Attorney from Idenix Pharmaceuticals, Inc., Centre National De La Recherche Scientifique and Universita Degli Studi Di Cagliari are of record.

Chain of title in the above-referenced application is evidenced by:

- (i) Assignments from the inventors to Idenix Pharmaceuticals, Inc., Centre National De La Recherche Scientifique and Universita Degli Studi Di Cagliari, as recorded on November 11, 2008 at reel 021819 frame 0136, reel 021819 frame 0145, and reel 021819 frame 0149;
- (ii) an Assignment and Agreement dated June 20, 2007 between Jean-Pierre Sommadossi, Idenix Pharmaceuticals, Inc., and Idenix (Cayman) Limited, which was recorded on May 8, 2009 at reel 022660 frame 0366;
- (iii) a Patent Assignment Nullification dated October 13, 2008 between Paolo LaColla and Idenix (Cayman) Limited, which was recorded on May 7, 2009 at reel 022655 frame 0356; and
- (iv) an Assignment Agreement dated March 4, 2009, between Idenix Pharmaceuticals, Inc., Idenix SARL, Idenix (Cayman) Limited, Centre National De La Recherche Scientifique, Universita Degli Studi Di Cagliari and L'Université Montpellier II, placing joint ownership in Idenix Pharmaceuticals, Inc., Centre National De La Recherche Scientifique, Universita Degli Studi Di Cagliari and L'Université Montpellier II, which was recorded on May 6, 2009 at reel 022644 frame 0923.

The Commissioner is hereby authorized to charge any fee due in connection with the filing of this and the attached papers, including the processing fee set forth in 37 C.F.R. §1.17(i), or to credit any overpayment, to Jones Day Deposit Account No. 50-3013 (referencing 417451-999016).

Respectfully submitted,

Date: *June 23, 2009*



For: Mark D. Kafka (Reg. No. 59,569)
Dale L. Rieger (Reg. No. 43,045)
JONES DAY
222 East 41st Street
New York, NY 10017
Tel. (212) 326-3778

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : LaColla, et al.
Title : 2' and 3'-Nucleoside Prodrugs for Treating
Flaviviridae Infections

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

STATEMENT BY RICHARD STORER UNDER 37 C.F.R. § 1.48(a)

Dear Sir:

I hereby declare:

1. I am making this Statement under 37 C.F.R. § 1.48(a) in connection with U.S. Patent Application No. 10/609,298, filed June 27, 2003; and the continuation U.S. Application Nos. 11/005,442; 11/005,466; 11/005,440; 11/005,443; 11/005,446; 11/005,472; and 11/005,444, filed December 6, 2004, each entitled "2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections", as listed in Appendix A attached hereto (hereinafter referred to as "the present applications").

2. I am a citizen of the United Kingdom and currently reside at the following address:

Richard Storer
Sandgate Point
The Leas
Folkstone, Kent
United Kingdom, CT 20 2 JE

3. An error was made in the present applications by naming the following individuals as joint inventors:

Paolo LaColla
Jean-Pierre Sommadossi
Richard Storer
Gilles Gosselin


4. The following is the correct list of joint inventors:

Jean-Pierre Sommadossi
Paolo LaColla
Gilles Gosselin

5. The inventorship error was made without any deceptive intent on my part.

6. I request that you remove me, Richard Storer, as an inventor for the present applications.

Date: _____



Richard Storer

APPENDIX A

Title	Application No.	Filing Date	Attorney Docket No.	Applicant
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	10/609,298	June 27, 2003	06171.105059 IDX 1017	LaColla et al.
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	11/005,442	December 6, 2004	06171.105126 IDX 1017 CON 2	LaColla et al.
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	11/005,466	December 6, 2004	06171.105126 IDX 1017 CON 3	LaColla et al.
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	11/005,440	December 6, 2004	06171.105126 IDX 1017 CON 4	LaColla et al.
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	11/005,443	December 6, 2004	06171.105126 IDX 1017 CON 5	LaColla et al.
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	11/005,446	December 6, 2004	06171.105126 IDX 1017 CON 6	LaColla et al.
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	11/005,472	December 6, 2004	06171.105126 IDX 1017 CON 7	LaColla et al.
2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections	11/005,444	December 6, 2004	06171.105126 IDX 1017 CON 8	LaColla et al.